Add BrightSurf on Google Email

Science News for June 4, 2016


UH Seidman Cancer Center experts to present data at 52nd ASCO Annual Meeting

Researchers from UH Seidman Cancer Center will present data on a new online tool for estimating individualized survival probabilities in patients with newly diagnosed glioblastoma. The studies also explore promising new treatments, including pembrolizumab for head and neck squamous cell carcinoma, and improve patient participation in c...

SourceUniversity Hospitals Cleveland Medical Center·DateJun 4, 2016
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Study shows why immune-boosting therapy doesn't work for everyone with widespread melanoma

A recent study published at ASCO found that gene dysregulation causes immune T cells to turn back to an immature state, making them less effective against metastatic melanoma. The researchers discovered over 60 epigenetic changes and 10 changes in gene activity that were most common among patients who didn't respond to immunotherapy.

SourceNYU Langone Health / NYU Grossman School of Medicine·DateJun 4, 2016
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

UTSW team find up to one-quarter of lung cancer patients ineligible for immunotherapy

Researchers at UT Southwestern Medical Center discovered that between 14 to 25 percent of lung cancer patients also have immune disease, making them unsuitable for immunotherapy treatments. This finding raises critical questions about the effectiveness and toxicity of these treatments among patients with autoimmune diseases.

SourceUT Southwestern Medical Center·JournalJAMA Oncology·DateJun 4, 2016

MD Anderson study identifies significant cost differences between breast cancer chemotherapy regimens

A new study from MD Anderson Cancer Center found substantial variation in costs of breast cancer treatment for different chemotherapy regimens, with insurer costs varying by as much as $20,354. Choosing equally effective but less costly regimens could impact the cost of breast cancer care nationally by $1 billion every year.

SourceUniversity of Texas M. D. Anderson Cancer Center·DateJun 4, 2016
DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

Moffitt: Radiation therapy with pembrolizumab, bevacizumab safe for glioma patients

Researchers at H. Lee Moffitt Cancer Center report a safe and effective treatment regimen for recurrent high-grade glioma brain tumors, with durable disease control in three patients. The combination of pembrolizumab, bevacizumab, and radiation therapy shows promise as a potential new approach to treating these patients.

SourceH. Lee Moffitt Cancer Center & Research Institute·DateJun 4, 2016